ME03539B - Multispecifični konstrukti anтitela - Google Patents

Multispecifični konstrukti anтitela

Info

Publication number
ME03539B
ME03539B MEP-2019-274A MEP2019274A ME03539B ME 03539 B ME03539 B ME 03539B ME P2019274 A MEP2019274 A ME P2019274A ME 03539 B ME03539 B ME 03539B
Authority
ME
Montenegro
Prior art keywords
gly
ser
multispecific
prt
pro
Prior art date
Application number
MEP-2019-274A
Other languages
German (de)
English (en)
French (fr)
Inventor
Pallavi Bhatta
Emma Dave
Sam Philip Heywood
David Paul Humphreys
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of ME03539B publication Critical patent/ME03539B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Description

LISTA SEKVENCI <br>[0297] <br>LIST SEKVENCI <br>[0297] <br>< 11 > UCB Biopharma SPRL <br>< 120> Mul tispecificni konstrukti antitela <br>< 130> G0228_ WO <br><160> 80 <br>< 170> Patentln verzija . 5 <br><210> 1 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 1 <br>Ser Gly Gly Gly G~y Thr Gly Gly Gly Gly Ser <br>1 5 10 <br><210> 2 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br>29 <400> 2 <br>Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser <br>l 5 10 <br><210> <br><211 > 8 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><22?> fleksibllni veznik <br><400> ? <br><210> 4 <br><211> 11 <br><212> PRT <br>8 Lya 1'hr Bis 'l' Ala Ala <br>l 5 <br><213> Vestacka sekvenca <br><220> <br><22?> fleksibllni veznik <br><400> 4 <br>?8? Lya rhr Ri.a t'hr ??? ?.:? Pro ??? i>ro Ala <br>l 5 10 <br><210> 5 <br><211> 18 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><22?> fleksibllni veznik <br><400> 5 <br>??? t.ya rhr Bis ??.: ??? i>ro Pro ??? Pro Ala ??r ??? Pro Pro ??• <br>1 S 10 lS <br>ProAla <br><210> 6 <br><211 > 25 <br><212> PRT <br><21 ?> Vestacka sekvenca <br>30 <220> <br><223> fleksibllni veznik <br><400> 6 <br>?8? Lya Th~ Bia ?h~ ??? Pro ?~? ??? i~o Al& Th~ ??? ?~? ?~? ??? <br>1 3 10 ? <br>??? Ala !'? ??? Pro ??? ??? ??? Ala <br><210> 7 <br><211> 30 <br><212> PRT <br>~? ~5 <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 7 <br>?8? Lya ??~ Sia ?h~ ??? ?~? ?~? ??• Pro Ala Gly I.ya Pz;o 'l'hr Leu <br>1 ! 10 13 <br>Tyr A8d ser ~ val ??t sar ??? 'fhr A.la !ily 'l'?r ??? 'ryr <br>20 25 30 <br><210> 8 <br><211> 31 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 8 <br>?8? I.ya 'l'h~ Bia 'l'h~ ??? Pro ?~? ??? Pz;o Al& Gly Lya ?~? 'l'h~ ?i? <br>1 ! 10 15 <br>Val A8d Val ser Val Val ??t Ala Glu val ?8? Gly '!'? ??? ??~ <br><210> 9 <br><211> 15 <br><212> PRT <br>~? 25 ?? <br><213> Vestacka sekvenca <br><220> <br>31 <22?> fleksibllni veznik <br><400> 9 <br>??? 1.?? 1'br Ri? Thr ??? ??? Val Glu ??? Pro Pro ??? Pro Ala <br>1. 5 1.0 1.5 <br><210> 10 <br><211> 26 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><22?> fleksibllni veznik <br><400> 10 <br>??? L?? 'I'?r Si.8 'rhr ??? Pro Arq ??• ?~ Glu Pro :Ly• Sez; ??• ??? <br>1 .5 10 1.5 <br>'l'hr 5'~ Pro Pro ??? ?~ ~.rq ??? Pro Al& <br>~? ~.s <br><210> 11 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><22?> fleksibllni veznik <br><400> 11 <br>??? :t.?? 'I'?z: Ri? t?r ??? Pz:o Ser ??• Pro Ala <br>1. 5 10 <br><210> 12 <br><211 > 7 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 12 <br>Ser Gly Gly Gly Gly Ser Glu <br>1. 5 <br>32 <210> 13 <br><211 > 6 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 13 <br><210> 14 <br><211 > 6 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 14 <br><210> 15 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 15 <br>??? Lya Thr ?i? Th.r Ser <br>1 5 <br>Ser Gly Gly Gly Gly Ser <br>1 5 <br>Ser Gly Gly Gly Qly Ser Gly Gly Gly Gly Ser <br>1 5 10 <br><210> 16 <br><211> 16 <br><212> PRT <br><213> Vestacka sekvenca <br>33 <220> <br><223> fleksibllni veznik <br><400> 16 <br>Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser <br>1 5 10 15 <br><210> 17 <br><211>21 <br><212> PRT <br><213> Artificial Sequence <br><220> <br><223> fleksibllni veznik <br><400> 17 <br>S.r Oly Gly Gly Oly S.r Oly Gly Gly Gly Ser Oly Gly Gly Gly Ser <br>1 ~ 10 ? <br>Gly Gly Gly Gly Ser <br>20 <br><210> 18 <br><211 > 26 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 18 <br>S.r Oly Gly Gly Oly S.r Oly Gly Gly Gly Ser Oly Gly Gly Gly Ser <br>1 ~ ~ ? <br>Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser <br><210> 19 <br><211> 11 <br><212> PRT <br>20 25 <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 19 <br>34 Ala Ala Ala Gly Ser Gly Gly Ala Ser Ala Ser <br><210> 20 <br><211> 16 <br><212> PRT <br>1 5 10 <br><21 ?> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><220> <br><221> misc_feature <br><222> (7) .• (7) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><400> 20 <br>Ala Ala Al& Oly Ser Gly ?&& Gly Gly Gly Ser Gly Ala Ser Ala Ser <br>1 5 10 15 <br><210> 21 <br><211> 21 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><220> <br><221 > misc_feature <br><222> (7) .. (7) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><220> <br><221 > misc_feature <br><222> (12) .. (12) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><400> 21 <br>Al& Al& Ala Cily Ser (?? ?.? Cily Cily (?? Ser ?.? Cily Gly (?? Ser <br>1 3 10 13 <br><210> 22 <br><211 > 26 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br>35 <223> Fleksibllni veznik <br><220> <br><221 > misc_feature <br><222> (7) .. (7) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><220> <br><221 > misc_feature <br><222> (12) .. (12) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><220> <br><221> misc_feature <br><222> (17) .. (17) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><400> 22 <br>Al& Ala Ala Cilly Sel:' Gly ??? Cilly Gly Gly Sel:' ??? Cilly Gly Gly Ser <br>1 ! 10 1! <br>XU. Gly Gly Gly s.r Gly Ala S.r Ala S~ <br>20 25 <br><210> 23 <br><211> 31 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><220> <br><221 > misc_feature <br><222> (7) .. (7) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><220> <br><221 > misc_feature <br><222> (12) .. (12) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><220> <br><221 > misc_feature <br><222> (17) .. (17) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><220> <br><221 > misc_feature <br><222> (22) .. (22) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><400> 23 <br>36 Ala Ala Ala Gly Se~ Gly ??? Gly aly G~y S•~ ??? Gly Gly Gly Ser <br>1 ! 10 1! <br>??& Gly Gly Gly ?? ??& Gly Gly Gly SU Gly Ala S.r Ala SU <br>20 2! ?? <br><210> 24 <br><211> 13 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><220> <br><221 > misc_feature <br><222> (7) .. (7) <br><223> ??? moze ?iti amino kiselina koja se prirodno javlja <br><400> 24 <br>Ala Ala Ala Gly Ser Gly ??& Se:r: Gly Ala Ser Ala Ser <br><210> 25 <br><211> 28 <br><212> PRT <br>1 5 10 <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 25 <br>Pro Gly Gly A8n A.l;fJ Gly D~ D~ Th~ Thr bl'iJ AriJ ??? IU& 'l'br Thr <br>1 ! 10 Hi <br>Dr Gly S.r su Pro Gly Pro nr GJ.:I su ?1? 'l'yr <br>20 25 <br><210> 26 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 26 <br>Ala 'l'hr t'hr t'hr Gly Ser Ser Pro CRy Pro 'l'hr <br>1 5 10 <br>37 <210> 27 <br><211 > 6 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><22?> Fleksibllni veznik <br><400> 27 <br><210> 28 <br><211> 21 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><22?> Fleksibllni veznik <br><400> 28 <br>Ala Thr Thr Thr Gly Ser <br>1 5 <br>Olu ?~? Se~ Gly ?~ %le S.~ ??~ Ile Aan S•~ ?~? ?~? Se~ Ly• Glu <br>1 5 10 1! <br>ser Bil J.yl s? l'ro <br>2D <br><210> 29 <br><211> 15 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><22?> Fleksibllni veznik <br><400> 29 <br>Gly 'l'hr Val Ala Ala Pro Se~ Val Phe :tle ??? Pro Pro Ser ??? <br>1 5 u ~ <br><210> ?? <br><211> 15 <br><212> PRT <br><21 ?> Vestacka sekvenca <br>38 <220> <br><223> Fleksibllni veznik <br><400> 30 <br>Gly Gly Gly Gly Ile Ala Pro Ser ??t val Gly Gly Gly G~y Ser <br>1 5 10 15 <br><210> 31 <br><211> 15 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 31 <br>Gly Gly Gly G~y Lya Val G~u Gly Ala Gly Gly Gly Gly Gly Ser <br>1 5 10 15 <br><210> 32 <br><211> 15 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 32 <br>Gly Gly Gly G~y Ser ??t L?? Ser ?i? Asp Gly Gly Gly Gly Ser <br>1 5 ~ ~ <br><210> 33 <br><211> 15 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 33 <br>Gly Qly Gly Gly Asn Leu Ile ?hr Ile Val Gly G . ly Gly Gly Ser <br>1 s u u <br><210> 34 <br><211> 15 <br><212> PRT <br>39 <213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 34 <br>Gly G~y Gly Gly V&l Val Pro Ser Leu Pro Gly Gly Gly Gly Ser <br>1 5 10 15 <br><210> 35 <br><211> 12 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 35 <br>Gly Gly Glu Lya Ser Ile Pro Gly G~y Gly Gly Ser <br>1 5 10 <br><210> 36 <br><211>18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 36 <br>?9 Pro :t.eu S.or ??r Az.-9 Pz.-o Pz.-o ??• lil'~:o ??. Gly Phe Pro S.r Val <br>1 !5 10 1!5 <br><210> 37 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 37 <br>??!: Pz.-o AI."YJ S.or I? '!?1: Ile MCiJ Ar9 Ar9 Hia Poro S.1: ?1:? Ser lAu <br>1 s 10 13 <br>'l'?r ??r <br>40 <210> 38 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 38 <br>t'hr Pro Ser ?i? Leu Ser Bia Ile Leu l>ro Ser ??? Gly Leu Pro i'hr <br>1 s 10 15 <br>??? Aan <br><210> 39 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 39 <br>Arq Pro Va1 Ser Pro Phe 1'tu: ??? Pro Arq l.eu Ser Aan Ser 'trp Leu <br>1 5 10 15 <br><210> 40 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 40 <br>Ser Pro Ala Ala ?i? Phe Pro ArCJ Ser Ile Pro ArCJ Pro Gly Pro :Ile <br>1 <br>10 <br>1S <br>41 <210> 41 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 41 <br>Al& Pro Qly Pro Ser Al& Pro S.r Bia Arq Sar Leu Pro Ser Arq Al& <br>1 ! 10 1!1 <br>??? Gly <br><210> 42 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 42 <br>Pro ? A.rl Ser Ile Hi.a ??. l.eu Hia Pro l.eu l.eu Val Ala Pro 1.811 <br>1 5 10 1! <br>Gly Al.a <br><210> 43 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 43 <br>Nat Pro Ser l.eu Ser Gly Val Leu Gln Val Arq 'l'yx Leu S.r Pro Pro <br>1 ! 10 15 <br>??? Leu <br><210> 44 <br>42 <211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 44 <br>Se.r Pro Gln ??r Pro Sez Pro Leu t'?r Leu ??r Leu Pro Pro Ris Pro <br>1 5 10 lS <br><210> 45 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 45 <br>Alln Pro Ser Leu Alln Pro Pro Ser ??r Leu Hia Ar!J Ala li'ro Ser Arq <br>1 5 10 15 <br><210> 46 <br><211> 17 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 46 <br>Leu Pro Trp Arq Thr Ser Leu Leu li'ro Ser Leu Pro :r.eu A:rq Arq Arq <br>1 s u u <br><210> 47 <br><211> 18 <br><212> PRT <br>43 <213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 47 <br>Pro Pro Leu Phe Al.a L?? G~y Pro Val Gly Leu x.eu Ser Arq Ser Phe <br><210> 48 <br><211> 18 <br><212> PRT <br>1 <br>l'ro Pro <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 48 <br>10 <br>Val Pro Pro Ala Pro Val Val S.r Leu ? Ser Ala lli? ?? ? Pro <br>1 s 10 15 <br>Pro Tyr <br><210> 49 <br><211> 17 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 49 <br>Leu Arq l'ro Thr Pro Pro Arq Val Argo Ser ???- ??r ??? Cys Pro 'l'hr <br>1 ~ 10 1! <br>l'ro <br>44 <br>1~ <210> 50 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 50 <br>?~? Aan Val Al& ?~• Val Le~ ?~? Le~ Leu Th~ Val ?~? ??? ?8? A8n <br>1 ~ 10 1! <br><210> 51 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Fleksibllni veznik <br><400> 51 <br>??• Aan Pro I.eu Leu Pro :Leu ??• Ala Ar9 Ser Pro Ala Val Ar9 Thr <br>1 5 10 lS <br>??? ?~? <br><210> 52 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Cvrsti veznik <br><400> 52 <br><210> 53 <br><211 > 4 <br><212> PRT <br>Gly Ala Pro Ala Pro Ala Ala Pro Ala Pro Ala <br>1 5 10 <br>45 <213> Vestacka sekvenca <br><220> <br><223> Cvrsti veznik <br><400> 53 <br><210> 54 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 54 <br>Pro Pro Pro Pro <br>1 <br>??? Leu ??? Leu Arq ??? frp Gly ??? Leu 'l'rp <br>l 5 10 <br><210> 55 <br><211> 11 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Al?umin vezujuci peptid <br><400> 55 <br>??? Ile ??? Leu Pro Arq 'l'rp Gly ??? Leu trp <br>l 5 10 <br><210> 56 <br><211> 15 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 56 <br>46 ??t Glu ??? Ile ??? Leu Pro Ar9 Trp Gly ??? :Leu Trp Gly ?8? <br>1 5 10 15 <br><210> 57 <br><211> 20 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 57 <br>Gln Ar9 L8u Net Qlu ?8? 11• ??? Leu Pr:-o ? 'frp Gly ??? Leu 'l'rp <br>1 5 10 1! <br>Glu ??? Up Glu <br>20 <br><210> 58 <br><211 > 20 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 58 <br>Gln Qly L8u tle Qly ?8? lle ??? ?.- P;r;o ? 'frp Gly ??? Leu 'l'rp <br>1 5 10 1! <br>Gly Acq Ser Val. <br>20 <br><210> 59 <br><211> 21 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> AI?umin vezujuci peptid <br><400> 59 <br>Gln Gly L8u tle Qly ?8? lle ??• L4N P;r;o ? 'frp CJly ??? Leu 'l'rp <br>1 5 10 1! <br>Gly ~ S•r Val Ly• <br>20 <210> 60 <br><211> 15 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><22?> Albumin vezujuci peptid <br><400> 60 <br>Glu ??? Ile ??? Leu Pro ?rq Trp Gly ??? Leu Trp Glu ??? .IUip <br>1 5 10 15 <br><210> 61 <br><211>18 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><22?> Albumin vezujuci peptid <br><400> 61 <br>Al:'q Leu *t Glu Alp :tle ??? :Leu ??;? ? ??;? Gly ??• J.tN ??? Qlu <br>1 3 10 13 <br><210> 62 <br><211> 16 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><22?> Albumin vezujuci peptid <br><400> 62 <br>Jfet Glu .1U1p Ile ??? Leu Pro Arq Trp Gly Cys Leu Trp Glu ??? .IUip <br>1 5 u u <br>48 <210> 63 <br><211> 15 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> A!?umin vezujuci peptid <br><400> 63 <br>.Net Glu ?8? Ile ??? Leu Pro Ar9 Trp Gly ??• Leu Trp Glu ??? <br>1 5 10 lS <br><210> 64 <br><211> 18 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuCi peptid <br><400> 64 <br>~~~~-~~~~~~~~~~~ <br>1 5 10 15 <br>?8? ??? <br><210> 65 <br><211> 20 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuCi peptid <br><400> 65 <br>Qlu V&l ? Ser .Phe ??• 'l'hz:-~ ,.rp .Pz:-o ??.? Glu :t.y• Sez:- ??• ?.?• <br>1 ~ 10 1~ <br>Pro ~ ~ Gly <br>20 <br><210> 66 <br><211> 20 <br><212> PRT <br><213> Vestacka sekvenca <br>49 <220> <br><223> Albumin vezujuCi peptid <br><400> 66 <br>k9 Ala t~o Qlu Se~ t?. V&l ??• ??~ 'l"Ep Glu 'l'h~ lle ??? t?. Qlu <br>1 ! 10 1! <br>Arg Se~ Glu Gln <br>.?? <br><210> 67 <br><211> 11 <br><212> PRT <br><21 ?> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 67 <br>Glu Net ??? Tyr Phe Pro Gly Ile ??? t'rp Net <br>?. 5 ?.? <br><210> 68 <br><211> 20 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> Albumin vezujuci peptid <br><400> 68 <br>Qly Qly Oly Oly Se~ Qly Qly Oly Gly Se~ Qly Qly Gly Gly Se~ Qly <br>1 ! ~ ~ <br>Gly Gly Gly Ser <br>20 <br><210> 69 <br><211> 16 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br>50 <400> 69 <br>Ser Gly Gly Gly Gly Ser Gly G1y Gly Gly Ser G1y Gly Gly Gly Ser <br>1 5 ~ u <br><210> 70 <br><211> 16 <br><212> PRT <br><213> Vestacka sekvenca <br><220> <br><223> fleksibllni veznik <br><400> 70 <br>Ser Gly G1y Gly Gly Ser Gly G1y Gly Gly Thr Gly G1y G~y G~y Ser <br>1 5 10 15 <br><210> 71 <br><211>10 <br><212> PRT <br><213 > Vestacko <br><220> <br><223> CDRH1 dAbH1 <br><400> 71 <br><210> 72 <br><211> 16 <br><212> PRT <br><213> vestacko <br><220> <br>Gly Ile Allp I.eu Ser Asn 'ryr Ala I.le ??n <br>1 5 10 <br><223> CDRH2 dAbH1 <br><400> 72 <br>Ile Ile Trp Ala Ser Gly 'fhr 'fhr Phe 'ryr Ala 'fhr t'rp Ala Lya Gly <br>1 s 10 15 <br><210> 73 <br>51 <211> 13 <br><212> PRT <br><213> Vestacko <br><220> <br><223> ?DR?? dAbH1 <br><400> 73 <br>?hr Val l>ro Gly 'fyr Ser Thr Ala Pro Tyr l'he ??? Leu <br>1 5 10 <br><210> 74 <br><211> 12 <br><212> PRT <br><213> Vestacko <br><220> <br><223> CDRL 1 d?? 1 <br><400> 74 <br>Gln Ser Ser l'ro Ser va.l Trp Ser Alm ??? Leu Ser <br>1 5 10 <br><210> 75 <br><211 > 7 <br><212> PRT <br><213> Artificial <br><220> <br><223> CDRL2 d?? 1 <br><400> 75 <br><210> 76 <br><211> 11 <br><212> PRT <br><213> Artificial <br>Glu Ala Ser Lya :teu Thr Ser <br>1 5 <br>52 <220> <br><223> CDRL? d?? 1 <br><400> 76 <br>Gly Gly Gly tyr Ser Ser Ile Ser ??? thr ~hr <br>?. s 10 <br><210> 77 <br><211> 121 <br><212> PRT <br><21 ?> Artificial <br><220> <br><223> Varijabllni domen teskog lanca anti Albumin antitela (nema ds) <br><400> 77 <br>Glu V.l Qln 1.tn1 Leu Qlu Se:r- Cilly Gly Gly Leu Val Cilln Pro Gly tily <br>1 ' ~ ~ <br>ser IAu Arq t.ev ser Cyt Ala va1 Ser G.ly Ile ?? t.?? s.r Atn ??:? <br>20 :2!1 30 <br>Ala tle ??n !'rp Val Arq Gln .Ua l'ro Gly l.ys Gly t.eu Glu txp Ile <br>?s •? •s <br>Gly :tle J:le 'l'rp Ala Ser Gly 'l'hr 'l'hr Phe Tyr Ala 'l'hr '!'rp ??. Ly4 <br>so 55 60 <br>Gly Arq ??? ?hr Ile Ser Arq ??? Aan Se.r l.ys Asn t'hr Val tyr Leu <br>6S 10 15 80 <br>G.ln ??t A8n S.r Leu Arq Ala Glu ?8? ??r Ala Val ??r ??r CYI Ala <br>85 90 95 <br>-~~~~~~~~~~~-~txp~ <br>100 10!1 110 <br>Gln Gly '!'?r Leu Val ?~ Val S.r Ser <br><210> 78 <br><211> 121 <br>115 120 <br>53 <212> PRT <br><213> Artificial <br><220> <br><223> Varijabllni domen teskog lanca anti Al?umin antetela (nema ds) <br><400> 78 <br>Gl11 Val Cilln Leu Leu Glu Sa:r Gly Gly Gly Leu Val Cilln :Pro Gly Cilly <br>1 3 ? ~ <br>Se.r Leu Arq Leu Se.r ??? Ala Val Ser Gly Ile Alrp Le'\1 Ser Aan 'l'yr <br>20 25 30 <br>Ala Ile Aan 'rrp V&l. A:rg Cilln ?1.? Pro Gly Lya ??? 1.811 1311.1 '1':rp Ile <br>35 40 45 <br>Gly tle 1le 'rrp Ala Se.r Gly Thr ?'?r Phe Ty:r Ala 'rhr 'trp Ala Lya <br>50 55 '? <br>G.ly Arq Pha 'l'hr Ile Se.r Arq A1rp Aan se.r Lya Aan 'l'hr Val ??r Leu <br>65 70 75 80 <br>Gln ?.t; .?? Ser loe!~ A:rg .U.a Qlu ??? ?hr Ala V.l 'tyr ??r ??? Ala <br>85 90 95 <br>ArcJ 'l'h.r val Pro Gly ??r se.r Thr Ala P.ro ??r Phe .up Leu ??:? Gly <br>100 105 110 <br><nn gly="" ??r="" leu="" val="" th.r="" va.l="" ser="" <br=""></nn>115 120 <br><210> 79 <br><211> 112 <br><212> PRT <br><213> Artificial <br><220> <br><223> Varijabllni domen lakog lanca anti Albumin antitela (nema ds) <br>54 <400> 79 <br>??? Ile Oln ?.t ?h~ Gln Se~ ?~? S.~ &?~ VaJ. Se~ Ala S.~ V&l Oly <br>1 .5 10 1.5 <br>??? Arg val 'I'?r Ile ??r ??? Gln S.r Sar Pro Ser Val 'l'rp Sar Aan <br>20 2$ ?? <br>??. :IAu Ser 'l'q:. ?t~: Gln Ciln Z.ya ?~? Gly Lya Ala ?~? loya Z..u :IAu <br>?s •? •s <br>lle ?t~ Glu Ala ??~ Lya J.e-g "rh~ ?? Gly V&l ?~? Se~ ? ??? Ser <br>50 55 60 <br>Gly ser Gly Sar Gly !'?r ?8? ??. ??.r :t..u fhr Ile Ser 8ar z..u Gln <br>65 70 75 80 <br>Pro Glu ??? Phe Al& 1'hr 'tyr 'tyr ??? Gly Gly Gly 'fyr Ser Ser Ile <br>85 90 95 <br>S.r ?8? 'rl\r '1'hr 1'?. Gly Gly Gly ??r Lya Val Glu Ile Lya ArQ !'hr <br>100 105 110 <br><210> 80 <br><211> 112 <br><212> PRT <br><213> Artificial <br><220> <br><223> Varijabllni domen lakog lanca anti Albumin antitela (nema ds) <br><400> 80 <br>55 ?8? Ile Gln ??t 'rhE' Gln Sez; Pz;o Sez: Sez: Val Sez; Ala Sez; Val Qly <br>1 3 10 13 <br>Up Arq val ?hr J:le ??r ??8 Gl.n Ser Ser Pro Ser val. '!'rp Ser Un <br>20 25 30 <br>Phe Leu. Se:~r ~ql '?r~r G1n Gln 1.?• P~ro Gly Ly• Ala P~ro Ly• Leu Leu. <br>?s •? •s <br>Il.e l'y:r Glu Al.a ser Lyl Leu 'l'?r Ser Gly Val Pro Ser Ar9 ??? Se:r <br>!? !5 60 <br>~~~~~??r~~~~~~~~~~ <br>6!1 70 7!1 80 <br>P:ro Glu ?8? ??. Ala ??r Ty:r 'l'yr ??8 Gly Gly Gly 'l'yr Ser Ser Ile <br>85 90 95 <br>S~ UP 'l'?r 'fhr ??. Gly ??• Gly 'fhr Ly• Val Glu Ile Lyl At'q Thr <br>100 10!1 110 <br>56

Claims (24)

1. Multispeclfični moleku!antltela obuhvatajući ili sastojeći se od: a) polipeptidnog lanca formule (1): ib) polipeptidnog lanca formule (ll): pri čemu: VH predstavlja varijabilni domen teškog lanca;CH, predstavlja domen konstantnog regiona teškog lanca, na primer, domen 1 istog; X predstavlja vezu lli veznik;Y predstavlja vezu ili veznik;v, predstavlja dsFv ili dsscFv;VL predstavlja varijabilni domen lakog lanca;Ct predstavlja domen iz konstantnog regiona lakog lanca, kao što je Ckappa;Vz predstavlja dsFv ili dsscFv.
2.Multlspeciflčni moleku!antitela prema patentnom zahtevu 1, pri čemu je X veznik.
3.Multispecifični moleku!antitela prema bilo kojem od patentnih zahteva od 1 do 2, pri čemu je Y veznik.
4.Multispeciflčni moleku!antitela prema bilo kojem od patentnih zahteva od 1 do 3, pri čemu v, je dsFv, i Vz je dsFv. S.
5. Multispeclflčnl moleku! antitela prema bilo kojem od patentnih zahteva od 1 do 3, pri čemu v, je dsscFv i Vz je dsscFv.
6.Multispecifičnl moleku! antitela prema bilo kojem od patentnih zahteva od 1 do 3, pri čemu v, je dsscFv i Vz je dsFv, ili pri čemu v, je dsFv, l Vz je dsscFv.
7.Multispecifični moleku! antitela prema bilo kojem od patentnih zahteva od 1 do 6, pri čemu je varijabilni domen lakog lanca ili varijabilni domen teškog lanca od v, spojen na X, na primer, putem peptldne veze.
8.Multtspeciflčnl moleku! antitela prema bilo kojem od patentnih zahteva od 1 do 7, pri čemu je varijabilni domen lakog lanca ili varijabilni domen teškog lanca od Vz spojen naY, na primer, putem pepttdne veze.
9. Multispecifičnimoleku! antttela prema bilo kojem od patentnih zahteva od 1 do 8, prt čemu su vartjabtlnt domeni lakog lanca iteškog lanca od v1 i/ili varijabilnidomene lakog lanca i teškog lanca od v2 povezaniputem disulfidne vezeizmeđu dva konstruisana ostatka cisteina. 59
10. Multispecifični moleku!antttela prema bilo kojem od patentnih zahteva od 1 do 9,pričemu su varijabilnidomeni teškog lanca i lakog lanca od v1 i/ili v2 povezani putem dtsulfidne veze između dva ostatka cisteina, prt čemu jepozicija para cisteinskih ostataka izabrana iz grupe obuhvatajući ili sastojeći se od : VH37 l VL95, VH44 t VL100, VH44 i VL105, VtAS l VL87, VH100 i VL50, VH100b j VL49, VH98 i VL46, VH101 i VL46, VH105 j VL43 j VH106 i VL57 (numertsanje prema Kabatu), prt čemu su vrednosti VH iVL nezavisno izabrane unutar datog v1 ili v2.
11. Multispecifični molekul antitela prema patentnom zahtevu 1O, prt čemu je pozicija para konstruisanlh ostataka cisteina VH44 iVL100.
12. Multispecifičnimoleku!antitela prema bilo kojem od patentnih zahteva od 1 do 11,pričemu je X pepttdnt veznik.
13. Multispectfičnimoleku!antitela prema patentnom zahtevu 12, prt čemu je X peptidniveznik izabran od SEK ID BR:1, 2, 69 i70.
14. Multispecifičnimoleku!antltela prema btlo kojem od patentnih zahteva 1 do13, prt čemu je Y peptidnt veznik.
15. Multispecifičnt moleku! antjtela prema patentnom zahtevu 14,prt čemu je Y peptidni veznik izabran od SEK ID BR:1, 2, 69 j 70.
16. Multispecifičnimoleku!antitela prema bilo kojem od patentnih zahteva 1 do 15, koji je tri-specifičan.
17. Tri-specifičnimoleku! antitela prema patentnom zahtevu 16, prt čemu svakiod trt vezujućih domena veže različite antigene.
18. Polinukleotid kojikodira multispecifičnimoleku!antitela prema bilo kojem od patentnih zahteva od 1 do 17.
19. Vektor kojiobuhvata polinukleotid definisan u patentnom zahtevu 18.
20. Ćelija domaćina koja obuhvata polinukleotid ili vektor iz patentnog zahteva 18 ili 19 respektivno.
21. Ćelija domaćina koja obuhvata dva lli trt vektora, svaki vektor obuhvata poltnukleottd koji kodira različiti lanac polipeptlda multispectftčnog molekula antitela prema bilo kojem od patentnih zahteva od 1 do 17.
22. Postupak koji obuhvata ekspresiju multispecifičnog molekula antitela tz ćelije domaćina deftnisanu u patentnom zahtevu 20 ill patentnom zahtevu 21.
23. Farmaceutska kompozicija, koja obuhvata multispectftčnimoleku!antitela prema bilo kojem od patentnih zahteva od 1 do 17 inajmanje jedan ekscipljent.
24. MulUspeclfični molekul antitela prema bilo kojem od patentnih zahteva od 1 do 17 lli farmaceutska kompozicija prema patentnom zahtevu 23,za upotrebu u tretmanu.
MEP-2019-274A 2014-06-25 2015-06-25 Multispecifični konstrukti anтitela ME03539B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411320.3A GB201411320D0 (en) 2014-06-25 2014-06-25 Antibody construct
EP15732228.0A EP3161007B1 (en) 2014-06-25 2015-06-25 Multispecific antibody constructs
PCT/EP2015/064409 WO2015197772A1 (en) 2014-06-25 2015-06-25 Multispecific antibody constructs

Publications (1)

Publication Number Publication Date
ME03539B true ME03539B (me) 2020-07-20

Family

ID=51410123

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-274A ME03539B (me) 2014-06-25 2015-06-25 Multispecifični konstrukti anтitela

Country Status (27)

Country Link
US (2) US11345760B2 (me)
EP (2) EP3556777B1 (me)
JP (1) JP6765974B2 (me)
KR (1) KR102271204B1 (me)
CN (1) CN106459216B (me)
AU (2) AU2015279128B2 (me)
BR (1) BR112016027585A2 (me)
CA (1) CA2951609C (me)
CL (1) CL2016003324A1 (me)
CY (2) CY1122175T1 (me)
DK (2) DK3161007T3 (me)
ES (2) ES2750649T3 (me)
GB (1) GB201411320D0 (me)
HR (2) HRP20191775T1 (me)
HU (2) HUE053457T2 (me)
IL (1) IL249003B (me)
LT (2) LT3556777T (me)
ME (1) ME03539B (me)
MX (1) MX375911B (me)
MY (2) MY176332A (me)
PL (2) PL3161007T3 (me)
PT (2) PT3161007T (me)
RS (2) RS59416B1 (me)
RU (1) RU2725812C2 (me)
SG (2) SG11201609678YA (me)
SI (2) SI3161007T1 (me)
WO (1) WO2015197772A1 (me)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2758432T3 (pl) * 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CA3022494A1 (en) 2016-05-01 2017-11-09 Ucb Biopharma Sprl Affinity engineered serum protein carrier binding domain
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CN113646051A (zh) 2018-10-16 2021-11-12 Ucb生物制药有限责任公司 重症肌无力的治疗方法
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
GB201906835D0 (en) 2019-05-15 2019-06-26 Ucb Biopharma Sprl Dry microparticles
WO2020254483A1 (en) 2019-06-20 2020-12-24 UCB Biopharma SRL Hplc-based detection of flocculation agents in a protein sample
WO2021023619A1 (en) 2019-08-02 2021-02-11 UCB Biopharma SRL Methods for purifying antibodies
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
IL296732A (en) 2020-03-27 2022-11-01 UCB Biopharma SRL Autonomous knob domain peptides
US20230176071A1 (en) 2020-05-08 2023-06-08 UCB Biopharma SRL Arrays and methods for identifying binding sites on a protein
GB202012991D0 (en) 2020-08-20 2020-10-07 Ucb Biopharma Sprl Cell culture processes
JP2023546071A (ja) 2020-10-13 2023-11-01 アルミラル・ソシエダッド・アノニマ 二重特異性分子およびそれを用いた処置方法
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
JP2023550596A (ja) 2020-11-02 2023-12-04 ユーシービー バイオファルマ エスアールエル 運動ニューロン神経変性障害の治療のための抗ｔｒｅｍ１中和抗体の使用
GB202018889D0 (en) 2020-12-01 2021-01-13 UCB Biopharma SRL Formulations
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
EP4288153A1 (en) 2021-02-04 2023-12-13 RQ Biotechnology Limited Antibodies
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
GB202103785D0 (en) 2021-03-18 2021-05-05 UCB Biopharma SRL Formulations
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
IL308100A (en) 2021-05-03 2023-12-01 UCB Biopharma SRL Antibodies
AU2022272406A1 (en) 2021-05-10 2023-11-02 UCB Biopharma SRL Process for the production of recombinant proteins
GB202107153D0 (en) 2021-05-19 2021-06-30 UCB Biopharma SRL Method for filling vials containing liquid drug products
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
AU2022393224A1 (en) 2021-11-18 2024-06-27 UCB Biopharma SRL Method for the treatment of progressive chronic interstitial lung disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023242238A1 (en) 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
AR130722A1 (es) 2022-10-11 2025-01-15 UCB Biopharma SRL Proceso para la producción de proteínas recombinantes
WO2024089277A2 (en) 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies
GB202304512D0 (en) 2023-03-28 2023-05-10 Univ Oxford Innovation Ltd Antibodies
GB202309920D0 (en) 2023-06-29 2023-08-16 Univ Oxford Innovation Ltd Antibodies
GB202316016D0 (en) 2023-10-19 2023-12-06 Univ Oxford Innovation Ltd Antibodies
GB202318647D0 (en) 2023-12-06 2024-01-17 Ucb Biopharma Sprl Cell culture processes
GB202318820D0 (en) 2023-12-08 2024-01-24 UCB Biopharma SRL Antibodies
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd
TW202540204A (zh) 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025238133A1 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Multispecific antibody with binding specificity for il-11 and il-17
WO2025248017A1 (en) 2024-05-31 2025-12-04 UCB Biopharma SRL Method of purifying recombinant proteins

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PT1049787E (pt) 1998-01-23 2005-04-29 Vlaams Interuniv Inst Biotech Derivados de anticorpos multipropositos
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6387981B1 (en) 1999-10-28 2002-05-14 3M Innovative Properties Company Radiopaque dental materials with nano-sized particles
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
CA2410551A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
WO2002008293A2 (en) 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX2008010561A (es) 2006-02-15 2009-03-02 Imclone Systems Inc Anticuerpos funcionales.
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
MX2009008222A (es) * 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
JP2010532764A (ja) 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
CN102164960A (zh) * 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013068571A1 (en) * 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
LT3161007T (lt) 2019-10-10
AU2019205981A1 (en) 2019-08-01
IL249003B (en) 2019-09-26
RS59416B1 (sr) 2019-11-29
MY176332A (en) 2020-07-29
JP2017520253A (ja) 2017-07-27
CN106459216B (zh) 2021-04-20
ES2866398T3 (es) 2021-10-19
PT3556777T (pt) 2021-03-19
CA2951609A1 (en) 2015-12-30
US11345760B2 (en) 2022-05-31
GB201411320D0 (en) 2014-08-06
PL3556777T3 (pl) 2021-07-12
SI3556777T1 (sl) 2021-03-31
LT3556777T (lt) 2021-04-12
EP3556777B1 (en) 2021-01-20
HRP20191775T1 (hr) 2019-12-27
ES2750649T3 (es) 2020-03-26
HUE053457T2 (hu) 2021-06-28
RU2020115720A (ru) 2020-07-22
AU2015279128A1 (en) 2016-12-01
SG10201911670QA (en) 2020-02-27
CA2951609C (en) 2022-02-22
JP6765974B2 (ja) 2020-10-07
SG11201609678YA (en) 2016-12-29
RU2020115720A3 (me) 2021-11-30
DK3161007T3 (da) 2019-10-14
CL2016003324A1 (es) 2017-08-18
RU2725812C2 (ru) 2020-07-06
EP3161007A1 (en) 2017-05-03
SI3161007T1 (sl) 2019-10-30
US20220267476A1 (en) 2022-08-25
WO2015197772A1 (en) 2015-12-30
EP3556777A1 (en) 2019-10-23
KR102271204B1 (ko) 2021-06-30
MX375911B (es) 2025-03-07
MX2016015952A (es) 2017-04-05
CN106459216A (zh) 2017-02-22
KR20170020367A (ko) 2017-02-22
BR112016027585A2 (pt) 2018-01-30
RS61493B1 (sr) 2021-03-31
US12428497B2 (en) 2025-09-30
RU2017102193A (ru) 2018-07-25
AU2019205981B2 (en) 2020-05-28
EP3161007B1 (en) 2019-08-07
HRP20210389T1 (hr) 2021-04-16
IL249003A0 (en) 2017-01-31
RU2017102193A3 (me) 2019-03-01
DK3556777T3 (da) 2021-04-12
CY1122175T1 (el) 2020-11-25
MY195318A (en) 2023-01-12
US20170204200A1 (en) 2017-07-20
AU2015279128B2 (en) 2019-05-16
HUE046027T2 (hu) 2020-01-28
CY1123932T1 (el) 2022-05-27
PL3161007T3 (pl) 2020-02-28
PT3161007T (pt) 2019-10-25

Similar Documents

Publication Publication Date Title
ME03539B (me) Multispecifični konstrukti anтitela
CN114206932B (zh) 修饰的双特异性抗cd3抗体
CA3008442C (en) Human immunodeficiency virus neutralizing antibodies
JP7109382B2 (ja) Ｔｉｇｉｔに対する抗体
ES2981730T3 (es) Agentes terapéuticos dirigidos y usos de los mismos
AU2018387741B2 (en) FC binding fragments comprising a PD-L1 antigen-binding site
MX2019000861A (es) Vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.
ME03541B (me) Liječenje fibrodisplazije ossificans progressiva
HRP20190817T1 (hr) Ang2-vezujuće molekule
HRP20210876T1 (hr) Anti-tmprss2 antitijela i fragmenti koji vezuju antigen
RU2018147413A (ru) PD-L1 специфические антитела
AR082892A1 (es) Dominios variables individuales de inmunoglobulina de union al factor de crecimiento endotelial vascular (vegf)
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
KR20220145323A (ko) Il-15/il-15ra에 기반한 이형이량체 단백질 복합체를 포함하는 면역사이토카인
CA3217738A1 (en) Antigen binding proteins specifically binding prame
CN115991778A (zh) 抗pd-l1抗体及其用途
EP3712179A1 (en) Binding unit targeting fibroblast activation protein alpha and application thereof
CA3091492A1 (en) Cd38 protein antibody and application thereof
CN114181297B (zh) 一种高亲和力的pd-1膜外区突变体的融合蛋白及其药物组合物和用途
JP5798199B2 (ja) 抗がん剤
WO2012177892A2 (en) Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
Poungpair et al. A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus
BR9707142A (pt) Polinucleotìdeo purificado, dna, vetor, célula hospedeira, linhagem celular de hibridoma, anticorpo monoclonal, processos para produzir exodus, para aumentar a resistência à infecção por vìrus de imonudeficiência humana (hiv), para tratamento de infecção por vìrus de imonodeficiência humana (hiv), para proteção de células progenitoras de medula óssea contra os efeitos citotóxicos e para tratamento de doenças mieloproliferativas, e, uso de produto de proteina de exodus.
JP2022540877A (ja) Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質
CN119836434A (zh) 抗SARS-CoV-2抗原结合多肽、多肽复合物及其使用方法